SCHEMBL16292225

SCHEMBL16292225

Fc1ccc(-c2nc(-c3ccccc3)c(-c3ccc(-c4[nH]c(-c5ccc(F)cc5)nc4-c4ccccc4)cc3)[nH]2)cc1

nearest known ligand 0.85

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK13 O15264 15/20 0.85
MAPK12 P53778 15/20 0.85
MAPK11 Q15759 15/20 0.85
MAPK14 Q16539 15/20 0.85
GCGR P47871 10/20 0.85
ALOX5 P09917 4/20 0.85
MAPK9 P45984 3/20 0.73
PRKD3 O94806 2/20 0.73
MAP4K4 O95819 2/20 0.73
FRK P42685 2/20 0.73
CSNK1A1 P48729 2/20 0.73
CSNK1D P48730 2/20 0.73
GSK3B P49841 2/20 0.73
PTK6 Q13882 2/20 0.73
CLK4 Q9HAZ1 2/20 0.73
PRKD2 Q9BZL6 1/20 0.73
RAF1 P04049 5/20 0.69
NOX1 Q9Y5S8 1/20 0.65
KDM4E B2RXH2 1/20 0.64
CIT O14578 1/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1629037 1.00 MAPK13 (0.85) MAPK13MAPK12MAPK11MAPK14GCGR
SCHEMBL9195042 0.92 MAPK14 (1.00) MAPK13MAPK12MAPK11MAPK14GCGR
SCHEMBL4552316 0.92 MAPK14 (1.00) MAPK13MAPK12MAPK11MAPK14GCGR
SCHEMBL19868948 0.91 MAPK14 (1.00) MAPK13MAPK12MAPK11MAPK14GCGR
SCHEMBL5074753 0.91 MAPK13 (0.83) MAPK13MAPK12MAPK11MAPK14GCGR
SCHEMBL16667652 0.89 MAPK13 (0.83) MAPK13MAPK12MAPK11MAPK14GCGR
SCHEMBL104130 0.89 MAPK13 (0.82) MAPK13MAPK12MAPK11MAPK14GCGR
Benzene SCHEMBL28852698 0.89 MAPK13 (0.82) MAPK13MAPK12MAPK11MAPK14GCGR
Methane SCHEMBL3278320 0.87 MAPK13 (0.79) MAPK13MAPK12MAPK11MAPK14GCGR
SCHEMBL3371979 0.87 MAPK14 (0.74) MAPK13MAPK12MAPK11MAPK14GCGR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10633369-B2 Method of inhibiting DYRK1B 4 SC AG (DE) 2020-04-28 US disclosed
US-20180201606-A1 METHOD OF INHIBITING DYRK1B 4 SC AG (DE) 2018-07-19 US disclosed
US-9951050-B2 Method of inhibiting DYRK1B 4 SC AG (DE) 2018-04-24 US disclosed
US-20140371251-A1 METHOD OF INHIBITING DYRK1B 4SC DISCOVERY GMBH (DE) 2014-12-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10633369-B2 Method of inhibiting DYRK1B SMO, GLI1, GRK2 MAPK13 750/4885MAPK12 1024/4885MAPK11 1236/4885
US-20180201606-A1 METHOD OF INHIBITING DYRK1B SMO, GLI1, GRK2 MAPK13 750/4885MAPK12 1024/4885MAPK11 1236/4885
US-20140371251-A1 METHOD OF INHIBITING DYRK1B SMO, GLI1, GRK2 MAPK13 750/4885MAPK12 1024/4885MAPK11 1236/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.